Claudius Mahr, D.O.


Executive Director, Institute for Advanced Cardiac Care; System Director of Heart Failure

University / Hospital Affiliation

Medical City Dallas, Texas


Dr. Claudius Mahr, FACC, FESC, FHFA, FRSM is a cardiologist at Medical City in Dallas, Texas specializing in the comprehensive, longitudinal care of patients with all etiologies of cardiovascular conditions, heart failure, and cardiomyopathy, utilizing the latest available medical, surgical and device therapies, including mechanical assist devices and heart transplantation. Dr. Mahr was recruited to Texas to serve as Executive Director of the Institute for Advanced Cardiac Care, as well as the System Director of Heart Failure at Medical City Healthcare. He has received formal fellowship training and board certification in Advanced Heart Failure and Transplant Cardiology, and has extensive experience in the care of patients with cardiovascular conditions. Having received numerous professional awards over his career, he is a fellow of the American College of Cardiology, the European Society of Cardiology, and the Royal Society of Medicine – London, to name a few. Dr. Mahr is an internationally recognized leader in his field, a physician-scientist serving on several scientific advisory boards and steering committees, and an invited faculty lecturer at numerous national and international scientific meetings. Dr. Mahr serves in leadership roles for various professional organizations. He is current the President – Elect of ASAIO. He is an active member of the American College of Cardiology, the European Society of Cardiology, the Heart Failure Association of the ESC, ASAIO, and the International Society for Heart and Lung Transplantation. He is the Cardiovascular Section Editor for ASAIO Journal, and serves in editorial roles for several other scientific publications.

Manuscripts & Publications

Factors associated with Acute Limb Ischemia in Cardiogenic Shock and downstream Clinical Outcomes: Insights from the Cardiogenic Shock Working Group

Our knowledge of ALI in CS remains incomplete. Most previous studies exploring ALI in CS are limited by small sample sizes or utilize large national datasets that lack CS specific details.6, 8, 9 We sought to leverage the Cardiogenic Shock Working Group (CSWG) Registry, a large, multi-center, contemporary dataset tailored to CS patients. Our objectives were to depict the current burden of ALI in CS, describe patient characteristics and procedural factors associated with the development of ALI, and study the impact of ALI on in-hospital outcomes

Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working Group

High capacity Impella heart pumps are capable of provide up to 5.5 liter/min of flow while upper body surgical placement allows for ambulation. Patients with advanced cardiogenic shock from acute myocardial infarction or heart failure requiring temporary mechanical circulatory support may benefit from upfront use of Impella 5.5 to improve overall survival, including native heart recovery or successful bridge to durable left ventricular assist device surgery or heart transplantation.

A Computational Investigation of the Effects of Temporal Synchronization of Left Ventricular Assist Device Speed Modulation with the Cardiac Cycle on Intraventricular Hemodynamics

Patients with advanced heart failure are implanted with a left ventricular assist device (LVAD) as a bridge-to-transplantation or destination therapy. Despite advances in pump design, the risk of stroke remains high. LVAD implantation significantly alters intraventricular hemodynamics, where regions of stagnation or elevated shear stresses promote thrombus formation. Third generation pumps incorporate a pulsatility mode that modulates rotational speed of the pump to enhance in-pump washout. We investigated how the timing of the pulsatility mode with the cardiac cycle affects intraventricular hemodynamic factors linked to thrombus formation.